Ghassemi Kaitlyn, Inouye Keiko, Takhmazyan Tatevik, Bonavida Victor, Yang Jia-Wei, de Barros Natan Roberto, Thankam Finosh G
Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA 90064, USA.
Gels. 2023 Oct 18;9(10):824. doi: 10.3390/gels9100824.
Increased prevalence of cardiovascular disease and potentially life-threatening complications of myocardial infarction (MI) has led to emerging therapeutic approaches focusing on myocardial regeneration and restoration of physiologic function following infarction. Extracellular vesicle (EV) technology has gained attention owing to the biological potential to modulate cellular immune responses and promote the repair of damaged tissue. Also, EVs are involved in local and distant cellular communication following damage and play an important role in initiating the repair process. Vesicles derived from stem cells and cardiomyocytes (CM) are of particular interest due to their ability to promote cell growth, proliferation, and angiogenesis following MI. Although a promising candidate for myocardial repair, EV technology is limited by the short retention time of vesicles and rapid elimination by the body. There have been several successful attempts to address this shortcoming, which includes hydrogel technology for the sustained bioavailability of EVs. This review discusses and summarizes current understanding regarding EV technology in the context of myocardial repair.
心血管疾病患病率的增加以及心肌梗死(MI)潜在的危及生命的并发症,促使出现了专注于心肌梗死后心肌再生和生理功能恢复的治疗方法。细胞外囊泡(EV)技术因其调节细胞免疫反应和促进受损组织修复的生物学潜力而受到关注。此外,EV在损伤后的局部和远距离细胞通讯中发挥作用,并在启动修复过程中起重要作用。源自干细胞和心肌细胞(CM)的囊泡因其在心肌梗死后促进细胞生长、增殖和血管生成的能力而备受关注。尽管EV技术是心肌修复的一个有前景的候选方法,但它受到囊泡保留时间短和被身体快速清除的限制。已经有几次成功的尝试来解决这一缺点,其中包括用于EV持续生物利用度的水凝胶技术。本综述讨论并总结了在心肌修复背景下关于EV技术的当前认识。